MindWalk (HYFT) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MindWalk (HYFT) has outperformed Rein Therapeutics (RNTX) over the past year, losing 23.5% versus a loss of 44.7%. Over five years, HYFT leads with a -78.3% price change compared with -96.2% for RNTX. MindWalk is the larger company by market cap ($70.2 million vs $68.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYFT | RNTX |
|---|---|---|
| Share price | $1.49 | $0.7899 |
| Market cap | $70.21M | $68.14M |
| 1-day change | +4.21% | +2.68% |
| YTD return | -21.43% | -33.68% |
| 1-year return | -23.53% | -44.65% |
| 5-year return | -78.27% | -96.19% |
| EPS (TTM) | $-0.26 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.99 | $2.18 |
| 52-week low | $0.99 | $0.694 |
| Distance from 52-week high | -50.16% | -63.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +190.57% | +659.59% |
| Average volume | 229.74K | 430.81K |
| Shares outstanding | 47.11M | 86.27M |
| Employees | 74 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HYFT has outperformed RNTX by 21.1 percentage points over the past year.
About MindWalk
HYFT stock →MindWalk Holdings Corp. operates as a bio-native AI company.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
HYFT vs RNTX FAQ
Which is bigger, MindWalk or Rein Therapeutics?
MindWalk (HYFT) is larger, with a market capitalization of $70.21M compared with $68.14M for Rein Therapeutics (RNTX).
Which stock has performed better over the past year, HYFT or RNTX?
HYFT returned -23.53% over the past 12 months, compared with -44.65% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are MindWalk and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.